FVR – Finnish Vaccine Research Ltd. is planning to restructure its organization in order to strengthen its future operations and growth potential in the global competitive market for vaccine research. FVR has on January 15th, 2024 submitted a proposal for employee cooperation and change negotiations. 

The planned reorganization focuses on clinical vaccine trial activities at the Helsinki and Pori clinics. The plans are to open one larger site in Helsinki, combining the current two smaller clinics, while also adapting the headcount and roles to the requirements of the new clinic. The plans also include the phased closure of the company’s Pori clinic by the end of 2025 at the earliest. This supports FVR’s ability to reallocate resources to geographical locations that are in line with the company’s strategy for growth and competitiveness. In addition, there are plans to improve operational efficiency by revising the company’s organizational model, roles and responsibilities. 

About 31 people are affected by the planned changes. FVR’s preliminary assessment is that a maximum of 11 people cannot be offered alternative work. The final impacts will be defined through the negotiations. 

“Our long-term goal is to make Finland a frontrunner in the international competitive market for vaccine research. This requires deep expertise and good ecosystem collaboration, but also efficient organizational structures and the development of our own network of clinics,” says FVR’s CEO Ilkka Haukijärvi.   

It is estimated that the negotiations will be concluded by mid-March, and their outcome will be announced separately. 

 
Further information: 
Marikka Nevamäki 
Chief Communications and Marketing Officer 
marikka.nevamaki@fvr.fi 
+358 40 417 96 84  

FVR – Finnish Vaccine Research Ltd. 
FVR is a special-assignment company of the Finnish state, specializing in vaccine research. The company was founded in 2022, building on the strong vaccine research expertise transferred from the Tampere University Foundation and the Finnish Institute of Health and Welfare (THL). The Finnish state owns 51% of the company and the Tampere University Foundation 49%. The Ministry of Social Affairs and Health (STM) is responsible for the ownership steering of the company. In 2023, FVR employed 114 professionals at 10 clinics and other locations across Finland. www.fvr.fi/en